<DOC>
	<DOC>NCT00993226</DOC>
	<brief_summary>The objective is to identify the optimal dose of SABER-Bupivacaine for postoperative pain control in patients undergoing hysterectomy on the basis of pharmacokinetics, efficacy and safety evaluations. The study duration consists of a screening period up to 14 days and a treatment period 14 days with a long term follow up visit at 6 months. The study will provide further data on the efficacy and safety of the product.</brief_summary>
	<brief_title>An International Trial to Evaluate the Efficacy and Safety of SABER-Bupivacaine for Postoperative Pain Control in Patients Undergoing Hysterectomy</brief_title>
	<detailed_description />
	<mesh_term>Pain, Postoperative</mesh_term>
	<mesh_term>Bupivacaine</mesh_term>
	<criteria>A planned elective, abdominal hysterectomy Patients suitable for general anaesthesia Known clinically significant hepatic, gastrointestinal, renal, haematological, urologic, neurological, respiratory, endocrine or cardiovascular system abnormalities Known serious uncontrolled illness: cancer, psychiatric or metabolic disturbances. History of cured localised malignancies is allowed (i.e. basal or squamous cell skin carcinoma, breast carcinoma or cervical carcinoma) Abnormal ECG Prolonged QT syndrome Current or regular use of analgesic medication for other indication(s)</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Postoperative pain</keyword>
	<keyword>Local anaesthesia</keyword>
	<keyword>Postoperative pain after open abdominal hysterectomy surgery</keyword>
</DOC>